Home / Featured / Hellenic Atherosclerosis Society Guidelines for the Diagnosis and Treatment of Dyslipidemias – 2023

Hellenic Atherosclerosis Society Guidelines for the Diagnosis and Treatment of Dyslipidemias – 2023

Katsiki N*, Filippatos TD*, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A, Garoufi A, Rallidis L, Richter D, Nomikos T, Kolovou G, Kypreos K, Chrysohoou C,
Tziomalos K, Skoumas I, Koutagiar I, Attilakos A, Papagianni M, Boutari C, Kotsis V, Pitsavos C, Elisaf M, Tsioufis K, Liberopoulos E | *Equal contribution

 

Table of Contents

Total Atherosclerotic Cardiovascular Disease (ASCVD) Risk
Laboratory Evaluation of Dyslipidemias
Lifestyle Recommendations for the Reduction of ASCVD Risk
Clinical Pharmacology of Lipid-Lowering Drugs
Lp(a) and ASCVD Risk
Familial Combined Hyperlipidemia (FCHL)
Familial Chylomicronemia Syndrome (FCS)
Familial Dysbetalipoproteinemia
Lysosomal Acid Lipase Deficiency (LAL-D)
Homozygous Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
Dyslipidemia in Acute Coronary Syndromes
Statin Use in Heart Failure
Prevention of Stroke
Management of Dyslipidemia in Patients with CKD
Management of Dyslipidemia in Women
Management of Dyslipidemia in the Elderly
Lipid Management in Diabetes
Dyslipidemia in Children and Adolescents
Dyslipidemia in Patients with HIV Infection
Dyslipidemia in Autoimmune Diseases
Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Statin Intolerance – Statin-Associated Muscle Symptoms
Therapeutic Targets and Treatment Algorithm in Patients with Dyslipidemia
References

 

 

Top